Baseline HBV load increases the risk of anti-tuberculous drug-induced hepatitis flares in patients with tuberculosis

Abstract

Hepatitis associated anti-tuberculous treatment (HATT) has been a main obstacle in managing patients co-infected with Mycobacterium tuberculosis and hepatitis B virus (HBV). Therefore, we evaluated the factors related to the severity of adverse effects during HATT, especially those associated with liver failure. A retrospective study was carried out at Tongji Hospital from 2007 to 2012. Increases in serum transaminase levels of >3, 5, and 10 times the upper limit of normal (ULN) were used to define liver damage as mild, moderate, and severe, respectively. Patients with elevated total bilirubin (TBil) levels that were more than 10 times the ULN (>171 μmol/L) with or without decreased (<40%) prothrombin activity (PTA) were diagnosed with liver failure. A cohort of 87 patients was analyzed. The incidence of liver damage and liver failure was 59.8% (n=52) and 25.3% (n=22), respectively. The following variables were correlated with the severity of hepatotoxicity: albumin (ALB) levels, PTA, platelet counts (PLT), and the use of antiretroviral therapies (P<0.05). Hypo-proteinemia and antiretroviral therapy were significantly associated with liver failure, and high viral loads were a significant risk factor with an odds ratio (OR) of 2.066. Judicious follow-up of clinical conditions, liver function tests, and coagulation function, especially in patients with high HBV loads and hypoalbuminemia is recommended. It may be advisable to reconsider the use of antiviral drugs failure during the course of anti-tuberculous treatment of HBV infection patients to avoid the occurrence of furious liver failure.

Keywords

hepatitis B virus infection / anti-tuberculous treatment / Mycobacterium tuberculosis / HBV DNA loading / hypoproteinemia

References

[1] DevarbhaviH, SinghR, PatilM, et al. . Outcome and determinants of mortality in 269 patients with combination anti-tuberculous drug-induced liver injury. J Gastroenterol Hepatol, 2013, 28(1): 161-167 PMID: 23020522

[2] ParkWB, KimW, LeeKL, et al. . Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. J Infection, 2010, 61(4): 323-329

[3] ChienJY, HuangRM, WangJY, et al. . Hepatitis C virus infection increases hepatitis risk during anti-tuberculous treatment. Int J Tuberc Lung Dis, 2010, 14(5): 616-621 PMID: 20392356

[4] PandeJN, SinghSPN, KhilnaniGC, et al. . Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax, 1996, 51(2): 132-136 PMID: 8711642 PMCID: 473016

[5] PanL, JiaZS, ChenL, et al. . Effect of anti-tuberculous therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus. World J Gastroenterol, 2005, 11(16): 2518-2521 PMID: 15832429 PMCID: 4305646

[6] YewWW, LeungCC. Antituberculosis drugs and hepatotoxicity. Respirology, 2006, 11(6): 699-707 PMID: 17052297

[7] BlumbergHM, BurmanWJ, ChaissonRE, et al. . American Thoracic Society, Centers for Disease Control and Prevention and Infectious. Diseases Society of America: Treatment of Tuberculosis. Am J Respir Crit Care Med, 2003, 167(4): 603-662 PMID: 12588714

[8] WongWM, WuPC, YuenMF. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology, 2000, 31(1): 201-206 PMID: 10613746

[9] WangJY, LiuCH, HuFC, et al. . Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infection, 2011, 62(6): 448-455

[10] SinglaR, SharmaSK, MohanA, et al. . Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res, 2010, 132(6): 81-86 PMID: 20693595

[11] AnandAC, SethAK, PaulM, et al. . Risk factors of hepatotoxicity during anti-tuberculosis treatment. Med J Armed Forces India, 2006, 62(1): 45-49 PMID: 27407844 PMCID: 4923276

[12] SunHY, ChenIL, GauCS, et al. . A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature. J Formos Med Assoc, 2009, 108(2): 102-111 PMID: 19251545

[13] TostmannA, BoereeMJ, AarnoutseRE, et al. . Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol, 2008, 23(2): 192-202 PMID: 17995946

[14] CaiY, YiJY, ZhouCH, et al. . Pharmacogenetic Study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculous drug induced liver injury: A meta-analysis. Plos One, 2012, 7(10): e47769 PMID: 23082213 PMCID: 3474796